Ardana's BPH drug effective with just two annual doses

Scottish drugmaker Ardana says that preliminary data from a Phase II study of its long-acting gonadotrophin antagonist Teverelix, indicates that only two maintenance treatments a year are required to effectively treat the symptoms of benign prostatic hyperplasia. The firm added that this is a considerable improvement over currently-available BPH therapies.

Previous studies have shown that the drug reduces testosterone levels to the low end of the normal range in a dose-dependent manner, thereby avoiding chemical castration and its associated symptoms.